Alector, Inc.
Alector is a U.S. biotechnology company developing therapeutic approaches for neurodegenerative diseases. Its research combines neuroscience, immune biology and technology intended to improve the delivery of therapeutics to the brain. The company is based in South San Francisco, California, and its common shares trade on Nasdaq under ALEC. Alector's drug discovery activities target biological mechanisms that may contribute to neurodegeneration, and the company works through internal development and selected external collaborations. Its treatment candidates and development priorities can change as research progresses.
Company at a glance
Corporate information
- Company entity
- Alector, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.alector.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: ALEC
neuroimmunology · brain delivery · biologics
neurodegeneration · neurology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Alector is a U.S. biotechnology company developing therapeutic approaches for neurodegenerative diseases. Its research combines neuroscience, immune biology and technology intended to improve the delivery of therapeutics to the brain. The company is based in South San Francisco, California, and its common shares trade on Nasdaq under ALEC. Alector's drug discovery activities target biological mechanisms that may contribute to neurodegeneration, and the company works through internal development and selected external collaborations. Its treatment candidates and development priorities can change as research progresses.
Business, technology & evidence
- SecuritiesNasdaq: ALEC
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Alector, Inc. ↗Alector, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.